




**TEXAS MEDICAID**  
**Clinical Edit Prior Authorization**  
**DPP-4 Inhibitors:**  
**alogliptin 25 mg (NESINA 25 MG), JANUVIA 100 MG,**  
**ONGLYZA 5 MG**

| <b>STEP 1: CLEARLY PRINT AND COMPLETE TO EXPEDITE PROCESSING</b>  |                               |
|---|-------------------------------|
| Date:   | Prescriber First & Last Name: |
| Patient First & Last Name:  | Prescriber NPI:               |
| Patient Address:  | Prescriber Address:           |
| Patient ID:   | Prescriber Phone:             |
| Patient Date of Birth:  | Prescriber Fax:               |
| <b>STEP 2: MEDICATION INFORMATION</b>   |                               |
| Medication Requested (Name):  | Quantity Requested:           |
| Dose Requested:   | Dosing Instructions:          |
| Patient's Primary Diagnosis: _____ ICD 10 Code: _____   |                               |
| Indicate the drug's formulary status: *(Formulary available at <a href="http://www.txvendordrug.com">www.txvendordrug.com</a> ) |                               |
| <input type="checkbox"/> Non-Preferred Drug ( <b>NPD or NAP Status, Go to Step 3 - PDL PA Criteria Applies</b> )                |                               |
| <b>OR</b> <input type="checkbox"/> Preferred Drug ( <b>Go to Step 4</b> )   |                               |
| <b>OR</b> <input type="checkbox"/> No Status, Drug is not in a Market Basket ( <b>Go to Step 4</b> )                            |                               |
| <b>OR</b> <input type="checkbox"/> N/A as this request is for a CHIP / PERINATE client ( <b>Go to Step 4</b> )                  |                               |
| <b>STEP 3: PDL PRIOR AUTHORIZATION CRITERIA FOR NON-PREFERRED PRODUCT</b>   |                               |
| 1. Has the client failed a 14-day treatment trial with at least 1 preferred agent in the last 180 days?                         |                               |
| <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #2)                                   |                               |
| 2. Is there a documented allergy or contraindication to preferred agents in this class?   |                               |
| <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Go to #3)                                   |                               |
| 3. Is the drug necessary for treatment of stage-4 advanced metastatic cancer and associated conditions?                         |                               |
| <input type="checkbox"/> Yes (Go to Step 4 Question 1) <input type="checkbox"/> No (Deny)                                       |                               |



**STEP 4: CLINICAL PRIOR AUTHORIZATION CRITERIA**

1. Is the client greater than or equal to ( $\geq$ ) 18 years of age?

Yes (Go to #2)

No (Deny)

2. Does the client have a diagnosis of Type II Diabetes in the past 730 days?

Yes (Go to #3)

No (Deny)

3. Does the client have a diagnosis of moderate renal failure in the last 730 days?

Yes (Deny)

No (Go to #4)

4. Does the client have a diagnosis of severe renal failure or End-Stage Renal Disease (ESRD) in the last 730 days?

Yes (Deny)

No (Go to #5)

5. Is the dose less than or equal to ( $\leq$ ) 1 tablet per day?

Yes (Approve – 365 days)

No (Deny)

**STEP 5: SIGN AND FAX TO: NAVITUS PRIOR AUTHORIZATION AT: 855-668-8553**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

If criteria not met, submit chart documentation with form citing complex medical circumstances.  
For questions, please call Navitus Customer Care at 1-877-908-6023.